This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Ocular (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
by Zacks Equity Research
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Options Traders Expect Huge Moves in Ocular (OCUL) Stock
by Zacks Equity Research
Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -7.14% and 10.31%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
by Zacks Equity Research
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
by Zacks Equity Research
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock
by Zacks Equity Research
Ocular Therapeutix (OCUL) needs investors to pay close attention to the stock based on moves in the options market lately.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -5.56% and 10.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0.00% and 85.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
Ocular Therapeutix (OCUL) Enters Oversold Territory
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on a bit of a cold streak lately
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on the move lately as the stock has risen by 38% in the past four weeks, and it is currently trading well above its 20-Day SMA
Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
by Zacks Equity Research
Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.